^
BIOMARKER:

BRAF V600E

i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF V600E
Pancreatic Cancer
cobimetinib
Sensitive: C4 – Case Studies
Cold Spring Harb Mol Case Stud - 6 days
BRAF V600E
CRC
cetuximab + encorafenib
Sensitive: A1 - Approval
FDA - 3 weeks
BRAF V600E
CRC
cetuximab + encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
dabrafenib
Sensitive: A1 - Approval
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
vemurafenib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
trametinib
Sensitive: A1 - Approval
BRAF V600E
Melanoma
encorafenib + binimetinib
Sensitive: A1 - Approval
BRAF V600E
NSCLC
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
GBM
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Biliary Tract Cancer
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Glioma
selumetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Astrocytoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
trametinib
Sensitive: A2 - Guideline
BRAF V600E
Ganglioglioma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
BRAF V600E
CRC
panitumumab + encorafenib
Sensitive: A2 - Guideline
BRAF V600E
CRC
trametinib + dabrafenib + panitumumab
Sensitive: A2 - Guideline
BRAF V600E
CRC
cetuximab + trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600E
Biliary Tract Cancer
pembrolizumab + lenvatinib
Sensitive: A2 - Guideline
BRAF V600E
GBM
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Melanoma
nivolumab + ipilimumab
Sensitive: B - Late Trials
BRAF V600E
Melanoma
pembrolizumab
Sensitive: B - Late Trials
BRAF V600E
CRC
trifluridine/tipiracil
Sensitive: B - Late Trials
BRAF V600E
CRC
cetuximab
Resistant: B - Late Trials
BRAF V600E
Melanoma
encorafenib
Sensitive: B - Late Trials
BRAF V600E
CRC
encorafenib
Sensitive: B - Late Trials
BRAF V600E
CRC
encorafenib + binimetinib
Sensitive: B - Late Trials
BRAF V600E
Melanoma
nivolumab
Sensitive: B - Late Trials
BRAF V600E
CRC
bevacizumab
Resistant: B - Late Trials
BRAF V600E
NSCLC
dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Neuroendocrine Tumor
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Neurofibrosarcoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Ovarian Serous Adenocarcinoma
encorafenib + binimetinib
Sensitive: C1 - Off-label
BRAF V600E
GBM
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Pancreatic Cancer
encorafenib + binimetinib
Sensitive: C1 - Off-label
BRAF V600E
Solid Tumor
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Cholangiocarcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
GBM
dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
LUAD
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Multiple Myeloma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
CRC
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
CRC
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Ovarian Cancer
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Ovarian Cancer
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Head and Neck Cancer
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
CRC
dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Cutaneous Melanoma
trametinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Carcinoma
dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Carcinoma
trametinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Papillary Carcinoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
Solid Tumor
encorafenib + binimetinib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Papillary Carcinoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
vemurafenib
Resistant: C1 - Off-label
BRAF V600E
Thyroid Gland Carcinoma
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Pancreatic Cancer
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Ocular Melanoma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
NSCLC
trametinib
Sensitive: C1 - Off-label
BRAF V600E
Gastric Cancer
vemurafenib
Sensitive: C1 - Off-label
BRAF V600E
Biliary Tract Cancer
trametinib
Sensitive: C1 - Off-label
BRAF V600E
Multiple Myeloma
vemurafenib + cobimetinib
Sensitive: C1 - Off-label
BRAF V600E
Glioma
trametinib + dabrafenib
Sensitive: C1 - Off-label
BRAF V600E
NSCLC
durvalumab
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Astrocytoma
selumetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Melanoma
pembrolizumab + trametinib + dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
CRC
cetuximab + vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
CRC
vemurafenib + panitumumab
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Hairy Cell Leukemia
dabrafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Solid Tumor
trametinib + dabrafenib + AT13387
Sensitive: C2 – Inclusion Criteria
BRAF V600E
CRC
trametinib + dabrafenib + PDR001
Sensitive: C2 – Inclusion Criteria
BRAF V600E
CRC
cetuximab + vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Melanoma
ipilimumab
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Hairy Cell Leukemia
vemurafenib
Sensitive: C2 – Inclusion Criteria
BRAF V600E
CRC
pembrolizumab
Sensitive: C2 – Inclusion Criteria